Shared vision for improving patient and staff safety and minimizing waste
FRISCO, Texas, Nov. 12 /PRNewswire/ -- The convergence of a world-class sales and service organization and a manufacturing organization will allow both companies to drive new growth opportunities and ultimately transform the way cancer fighting drugs are prepared and administered. The combination of Primus Innovations, Inc. solutions, sales, and services with Health Robotics engineering, software and robotic chemotherapy compounding technology "CytoCare(TM)", will enable a new standard of precision, accuracy, safety, and price efficiencies in chemotherapy admixtures.
Jack Risenhoover, Health Robotics Managing Principal, described the trampoline effect of the combination as a "powerful tool in the battle against cancer. We are particularly pleased that Primus Innovations has selected CytoCare as its exclusive solution for chemotherapy compounding for hospitals and outpatient infusion centers. Primus' experience in outsourcing will be a significant advantage for CytoCare customers."
Steve Bohannon, Primus Innovations, Inc. CEO and President, said, "Health Robotics has designed an incredible product that tilts the scales in the battle against cancer. In CytoCare we have a rare triple win: more accurate infusions for patients, a far safer environment for pharmacists and technicians and better economics and regulatory compliance for hospitals, clinics and physicians. We are incredibly pleased to be the exclusive distributor and service provider for CytoCare in North America."
CytoCare provides unparalleled benefits for patients, staff and pharmacists. The sterile robotic environment minimizes manual interaction and the associated risk of contamination. It supports patient-specific dosing, by using the patient's unique physical profile. Thus, the medication regimen is tailored and accurate with swifter, more effective results.
Moreover, dosing accuracy is enhanced with multiple and redundant safety checks further protecting the patient from potential medication errors. There are several hundred discrete data elements of the preparation process that are automatically tracked and saved as part of the permanent electronic medical record. To address USP 797 and other regulatory standards CytoCare provides an audit trail for record keeping purposes. CytoCare generates significant, immediate savings through FTE savings, reduction of redundant components from closed transfer devices, and efficiently using partial drug vials with automated time/date stamps and beyond use expiration alerts based on user defined protocols.
Primus Innovations and Health Robotics will be showcasing the CytoCare robot at the ASHP 42nd Annual Mid Year clinical meeting and exhibition in Las Vegas December 2-6th at booth #2644.
Primus Innovations, Inc., located in Frisco, Texas is the pre-eminent provider of automation, technology and services to the Oncology Industry. Primus is a strategic business partner to its customers offering a full suite of professional services encompassing all of the elements of support and outsourcing that our customers may require allowing them to focus on their core business. Primus also provides flexible financing programs which are designed to meet their customer economic requirements. For more information please visit: http://www.primusinnovations.com
About Health Robotics:
Health Robotics is the worldwide leader in patient specific, robotic chemotherapy admixtures. Its advanced technology and innovative engineering enhances sterility, delivers accurate doses for patients and helps protect clinicians from exposure to cytotoxic agents that can occur during manual compounding. http://www.healthrobotics.net
|SOURCE Primus Innovations, Inc.|
Copyright©2007 PR Newswire.
All rights reserved